TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).

ABSTRACT: The aim of the study was to evaluate the phenotypic CTCs heterogeneity (TTF-1⁺ and/or CD56⁺) in SCLC patients and correlate it with the CellSearch. Peripheral blood was obtained from 108 consecutive patients. CTCs were detected by CellSearch and double-immunofluorescence using anti-CD45, anti-TTF-1 and anti-CD56 antibodies. Before chemotherapy TTF-1⁺/CD45^-, CD56⁺/CD45^- and TTF-1⁺/CD56⁺ CTCs were detected in 66(61.1%), 55(50.9%) and 46(42.6%) patients, respectively; 60.2% of patients were CellSearch⁺. Among the 22 patients with 0 CTCs/7.5?ml on CellSearch, TTF-1⁺/CD45^-, CD56⁺/CD45^- and TTF-1⁺/CD56⁺ CTCs were detected in 8(36.4%), 6(27.3) and 6(27.3%) patients, respectively; no CK⁺/EpCAM⁺ or TTF1⁺/EpCAM⁺ CTCs were detected in these patients. One-chemotherapy cycle decreased both the number of positive patients (p?- CTC subpopulations and, thus, undetectable by CellSearch. These CTC subpopulations are dynamically correlated with treatment efficacy and disease-progression.

SUBMITTER: Messaritakis I 

PROVIDER: S-EPMC5368597 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature